- Trial Phase
- Filed/PDUFA (Phase 3 completed)
- Time to Market
- PDUFA target action date is February 12, 2027. If approved, commercial launch would likely follow within weeks to months thereafter.
- Why 8/10
- The next hard, dated catalyst is the FDA PDUFA target action date of February 12, 2027 (~5 months away), a binary approval/rejection decision on the NDA for tinlarebant in Stargardt disease — the company's lead and most advanced asset, making this a make-or-break event for a single-product biotech.
The PDUFA date of February 12, 2027, is the single most important catalyst — a binary approval/rejection decision on the first potential treatment for Stargardt disease. Monitor for any FDA Advisory Committee meeting announcement and the planned Commercial Day in September 2026 for launch preparation details. The stock's ~$7B market cap suggests significant approval expectations are already priced in, limiting upside surprise potential.
Price Chart
Executive Summary
Tinlarebant is Belite Bio's lead drug candidate — an oral RBP4 antagonist targeting Stargardt disease (STGD1), a rare inherited retinal disease with no approved treatments. The Phase 3 DRAGON trial met its primary endpoint, and the FDA accepted the NDA with Priority Review, setting a PDUFA target action date of February 12, 2027. The company also has ongoing trials in geographic atrophy (PHOENIX, Phase 3, 530 subjects enrolled) and a second STGD1 trial (DRAGON II, Phase 2/3, 73 subjects enrolled). With a ~$7B market cap, strong institutional backing, ~$780M cash position, and a Strong Buy analyst consensus (mean target $227), the stock's near-term trajectory hinges entirely on the February 2027 PDUFA decision.
How It Works
Tinlarebant is an oral pill that blocks a protein called RBP4 (retinol-binding protein 4), which normally transports vitamin A from the liver to the eye. In Stargardt disease, excess vitamin A in the retina builds up toxic byproducts (called bisretinoids/A2E) that kill light-sensing cells and cause progressive vision loss. By reducing the amount of vitamin A reaching the retina, tinlarebant slows or stops the accumulation of these toxins — essentially starving the disease process while preserving normal vision function elsewhere in the body.
Trial Status
Phase 3 DRAGON trial (NCT05244304) in adolescent Stargardt disease completed with 104 patients enrolled; met primary endpoint. NDA submitted and accepted by FDA with Priority Review. Secondary qAF imaging data showed tinlarebant-treated subjects had stable-to-slightly-decreased qAF (~2%) vs ~20% increase for placebo at month 25. DRAGON II (Phase 2/3, STGD1) fully enrolled with 73 subjects. PHOENIX (Phase 3, geographic atrophy) fully enrolled with 530 subjects; interim analysis expected.
The Two-Sided Case
Upcoming Catalysts
- PDUFA target action date: February 12, 2027 — FDA approval decision on tinlarebant for Stargardt disease
- Commercial Day (September 2026) — launch preparation update
- PHOENIX GA trial interim analysis readout (timing TBD)
- DRAGON II trial data readout (timing TBD)
- Potential FDA Advisory Committee meeting announcement
Source Filing
The SecBot filing or press-release report that triggered this drug report:
Belite Bio, Inc PRESS-RELEASE BLTE ·Originating report